Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 190Lung Neoplasms 67Ovarian Neoplasms 64Breast Neoplasms 38Fallopian Tube Neoplasms 33Small Cell Lung Carcinoma 31Parkinson Disease 4, Autosomal Dominant Lewy Body 27Carcinoma, Ovarian Epithelial 24Uterine Cervical Neoplasms 22Triple Negative Breast Neoplasms 22Squamous Cell Carcinoma of Head and Neck 19Neuroblastoma 17Carcinoma 17Adenocarcinoma of Lung 17Neoplasm Metastasis 15Endometrial Neoplasms 14Neoplasms 12Head and Neck Neoplasms 11Recurrence 8Peritoneal Neoplasms 8Carcinoma, Transitional Cell 8Esophageal Neoplasms 7Central Nervous System Neoplasms 7Brenner Tumor 7Urinary Bladder Neoplasms 6Lung Diseases 6Adenocarcinoma, Bronchiolo-Alveolar 6Thoracic Neoplasms 5Testicular Neoplasms 5Respiratory Tract Neoplasms 5

Interventions

pegfilgrastim 1Taxes 1Platinum 1Paclitaxel 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Doxorubicin 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Recurrent Uterine Corpus Carcinoma × Carboplatin × Clear all
NCT00063999 2021-10-19

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

GOG Foundation

Phase 3 Completed
1,381 enrolled 12 charts
Gynecologic

Recurrent Uterine Corpus Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡